Zerlasiran

Silence Therapeutics has paused the Phase III development of zerlasiran, its RNA-silencing therapy for cardiovascular diseases, until securing a strategic partnership, extending their cash runway into 2027.

Two novel therapies - oral muvalaplin and injectable zerlasiran - demonstrate remarkable efficacy in lowering lipoprotein(a) levels by 80-90% with minimal side effects in clinical trials.

Zerlasiran, a gene-silencing therapy, demonstrated sustained reductions in lipoprotein(a) [Lp(a)] levels through 60 weeks in the ALPACAR-360 trial.

Zerlasiran, a novel siRNA, significantly reduced time-averaged lipoprotein(a) levels by over 80% in a Phase 2 trial, offering a potential treatment for elevated Lp(a).

Zerlasiran, a GalNAc-conjugated siRNA, significantly reduced lipoprotein(a) levels by 80-85% in patients at high risk of atherosclerotic cardiovascular disease.